Evidence map›Paper›PMID 42492514›Full record

ArticleStem cell reports2026

Allogeneic iPSC-derived γδT cells demonstrate antitumor efficacy against patient-derived tissues.

Ryoko Futai, Michiyo Koyanagi-Aoi, Aito Nakahashi, Daiki Katsura, Manabu Horikawa, Kazumasa Horie, Yoshihiro Kakeji, Yuzo Kodama, Takashi Aoi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryoko FutaiDivision of Stem Cell Medicine, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan; Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan.
Michiyo Koyanagi-AoiDivision of Stem Cell Medicine, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan; Division of Advanced Medical Science, Graduate School of Science, Technology and Innovation, Kobe University, Kobe, Hyogo, Japan; Center for Human Resource Development for Regenerative Medicine, Kobe University Hospital, Kobe, Hyogo, Japan.
Aito NakahashiDivision of Stem Cell Medicine, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan.
Daiki KatsuraDivision of Stem Cell Medicine, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan; Division of Urology, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan.
Manabu HorikawaDivision of Stem Cell Medicine, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan; Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan.
Kazumasa HorieDivision of Stem Cell Medicine, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan; Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan.
Yoshihiro KakejiDivision of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan.
Yuzo KodamaDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan.
Takashi AoiDivision of Stem Cell Medicine, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan; Division of Advanced Medical Science, Graduate School of Science, Technology and Innovation, Kobe University, Kobe, Hyogo, Japan; Center for Human Resource Development for Regenerative Medicine, Kobe University Hospital, Kobe, Hyogo, Japan; Division of Signal Pathways, Biosignal Research Center, Kobe University, Kobe, Japan. Electronic address: takaaoi@med.kobe-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various immunotherapies have been developed to treat malignant tumors, and autologous CAR-T cell therapy is clinically used for certain malignancies. However, their efficacy against solid tumors is limited. γδT cells are recognized for their potent tumor cytotoxicity and MHC-unrestricted activity. We successfully induced γδT cells from iPS cells and demonstrated their cytotoxicity against colorectal cancer cell lines in vitro. However, cancer cell lines often lack critical tumor characteristics such as heterogeneity and drug sensitivity. In contrast, patient-derived cancer organoids retain many features of the patient's tumor tissues. This study evaluated the cytotoxicity of allogeneic iγδT cells against cell lines and organoids, in vitro and in vivo. iγδT cells showed 70%-90% cytotoxicity against cell lines and organoids in vitro. In vivo, local and intravenous administration of iγδT cells suppressed tumor growth by 70%-100%, highlighting their potential as a novel immunotherapy for colorectal cancer.

Indexed as

Colorectal NeoplasmsInduced Pluripotent Stem CellsIntraepithelial LymphocytesReceptors, Antigen, T-Cell, gamma-deltaAllogeneic CellsAnimalsCell Line, TumorCytotoxicity, ImmunologicHumansImmunotherapy, AdoptiveMiceOrganoidsXenograft Model Antitumor AssaysReceptors, Antigen, T-Cell, gamma-deltacolorectal cancerimmune cell therapyiPSCspatient-derived organoidsγδT cells

Identifiers

PMID42492514
PMCPMC13476892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.